Article Figures & Data
Figures
- Figure 1
Strategy for evaluating statin-related myopathy.
Tables
Endocrine myopathies Hyperthyroidism Hypothyroidism Drug or toxic myopathies Metabolic myopathies Mitochondrial myopathies Muscular dystrophies Infectious myositis Neuropathies and neurologic syndromes Paraneoplastic syndromes Other connective tissue disorders Miscellaneous Amyloidosis Sarcoidosis Musculoskeletal Weakness Muscle pain or tenderness Muscle atrophy Arthralgias Arthritis Gastrointestinal Dysphagia Reflux Dysmotility Cutaneous Rash Calcification Cardiac Arrhythmias Congestive failure Pulmonary Interstitial lung disease Aspiration pneumonia Interstitial fibrosis General Fever Fatigue Weight loss Raynaud phenomenon Antibody Antigen (tRNA synthetase) Prevalence in idiopathic inflammatory myopathy (%) Jo-1 Histidyl 20–30 PL-7 Threonyl <5 PL-12 Alanyl <5 OJ Isoleucyl < 5 EJ Glycyl < 5 KS Asparaginyl < 1 Try Tyrosyl < 1 Zo Phenylalanyl < 1
Jump to section
- Article
- ABSTRACT
- FOCUSING THE EVALUATION
- CASE 1: SLOWLY PROGRESSIVE WEAKNESS
- CASE 2: MILD MYALGIA WITHOUT WEAKNESS
- CLASSIFYING MYOSITIS
- CASE 3: WEAKNESS, VERY HIGH CK ON A STATIN
- CASE 4: FEVER, NEW ‘RHEUMATOID ARTHRITIS,’ AND LUNG DISEASE
- CASE 5: FEVER, UNDIAGNOSED LUNG DISEASE, NO MYOSITIS
- CASE 6: DERMATOMYOSITIS, RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE
- Footnotes
- REFERENCES
- Figures & Data
- Info & Metrics
Related Articles
Cited By...
- No citing articles found.